Management of malignant glioma - current concepts

被引：0
作者：
Schmidt-Graf, F. [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Neurol Klin, D-81675 Munich, Germany
来源：
NERVENHEILKUNDE | 2010年 / 29卷 / 12期
关键词：
Glioblastoma; glioma; therapy; PHASE-II TRIAL; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; ANTICOAGULANT-THERAPY; RADIOTHERAPY; RISK; CONCOMITANT; EFFICACY; TUMORS; ACID;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Therapy of malignant glioma has changed and developed further in the last years. Standard therapy consists of operation with consecutively radiochemotherapy and chemotherapy in WHO grade IV glioma, and either radiotherapy or chemotherapy in grade III glioma. Older patients, who have a worse prognosis, should be considered separately. In case of recurrent disease, further therapy should be discussed individually with more and more therapeutically options. Symptomatic and supportive treatment must not be neglected and should be always reconsidered and optimized.
引用
收藏
页码：815 / 819
页数：5
相关论文
共 26 条
  • [1] THE RISK AND EFFICACY OF ANTICOAGULANT-THERAPY IN THE TREATMENT OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH PRIMARY MALIGNANT BRAIN-TUMORS
    ALTSCHULER, E
    MOOSA, H
    SELKER, RG
    VERTOSICK, FT
    [J]. NEUROSURGERY, 1990, 27 (01) : 74 - 77
  • [2] Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
    Batchelor, Tracy T.
    Duda, Dan G.
    di Tomaso, Emmanuelle
    Ancukiewicz, Marek
    Plotkin, Scott R.
    Gerstner, Elizabeth
    Eichler, April F.
    Drappatz, Jan
    Hochberg, Fred H.
    Benner, Thomas
    Louis, David N.
    Cohen, Kenneth S.
    Chea, Houng
    Exarhopoulos, Alexis
    Loeffler, Jay S.
    Moses, Marsha A.
    Ivy, Percy
    Sorensen, A. Gregory
    Wen, Patrick Y.
    Jain, Rakesh K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) : 2817 - 2823
  • [3] Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
    Brandes, A. A.
    Tosoni, A.
    Cavallo, G.
    Bertorelle, R.
    Gioia, V.
    Franceschi, E.
    Biscuola, M.
    Blatt, V.
    Crino, L.
    Ermani, M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1155 - 1160
  • [4] RISK OF INTRACRANIAL HEMORRHAGE IN GLIOMA PATIENTS RECEIVING ANTICOAGULANT-THERAPY FOR VENOUS THROMBOEMBOLISM
    CHOUCAIR, AK
    SILVER, P
    LEVIN, VA
    [J]. JOURNAL OF NEUROSURGERY, 1987, 66 (03) : 357 - 358
  • [5] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
    Friedman, Henry S.
    Prados, Michael D.
    Wen, Patrick Y.
    Mikkelsen, Tom
    Schiff, David
    Abrey, Lauren E.
    Yung, W. K. Alfred
    Paleologos, Nina
    Nicholas, Martin K.
    Jensen, Randy
    Vredenburgh, James
    Huang, Jane
    Zheng, Maoxia
    Cloughesy, Timothy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4733 - 4740
  • [6] Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
    Hamer, Philip C. De Witt
    [J]. NEURO-ONCOLOGY, 2010, 12 (03) : 304 - 316
  • [7] ACNU-based chemotherapy for recurrent glioma in the temozolomide era
    Happold, Caroline
    Roth, Patrick
    Wick, Wolfgang
    Steinbach, Joachim P.
    Linnebank, Michael
    Weller, Michael
    Eisele, Guenter
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2009, 92 (01) : 45 - 48
  • [8] MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME
    Diserens, A
    Gorlia, T
    Hamou, M
    de Tribolet, N
    Weller, M
    Kros, JM
    Hainfellner, JA
    Mason, W
    Mariani, L
    Bromberg, JEC
    Hau, P
    Mirimanoff, RO
    Cairncross, JG
    Janzer, RC
    Stupp, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) : 997 - 1003
  • [9] Radiotherapy for glioblastoma in the elderly
    Keime-Guibert, Florence
    Chinot, Olivier
    Taillandier, Luc
    Cartalat-Carel, Stephanie
    Frenay, Marc
    Kantor, Guy
    Guillamo, Jean-Sebastien
    Jadaud, Eric
    Colin, Philippe
    Bondiau, Pierre-Yves
    Menei, Philippe
    Loiseau, Hugues
    Bernier, Valerie
    Honnorat, Jerome
    Barrie, Maryline
    Mokhtari, Karima
    Mazeron, Jean-Jacques
    Bissery, Anne
    Delattre, Jean-Yves
    Lacomblez, L.
    Levy-Soussan, M.
    Mallet, A.
    Houssard, C.
    Delgadillo, D.
    Poitou, M.
    Hoang-Xuan, K.
    Sanson, M.
    Carpentier, A. F.
    Laigle-Donadey, F.
    Taillibert, S.
    Cornu, P.
    Omuro, A.
    Capelle, L.
    Boch, A. -L.
    Duffau, H.
    Simon, J. -M.
    Medioni, J.
    Broet, P.
    Schmitt, A.
    Garat, E.
    Mathieu, P.
    Camille, N.
    Collin, J. -P.
    Bailet, B.
    Ciais, C.
    Fauchon, F.
    Lebrun, C.
    Guesdan, G.
    Stadelmaier, N.
    Lombard, I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) : 1527 - 1535
  • [10] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
    Kreisl, Teri N.
    Kim, Lyndon
    Moore, Kraig
    Duic, Paul
    Royce, Cheryl
    Stroud, Irene
    Garren, Nancy
    Mackey, Megan
    Butman, John A.
    Camphausen, Kevin
    Park, John
    Albert, Paul S.
    Fine, Howard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 740 - 745
123